Matthew Fox1, Marc Brown2, Nicholas Golda3, Dori Goldberg4, Christopher Miller5, Melissa Pugliano-Mauro6, Chrysalyne Schmults7, Thuzar Shin5, Thomas Stasko8, Yaohui G Xu9, Kishwer Nehal10. 1. Division of Dermatology at Dell Medical School, University of Texas at Austin, Austin, Texas. Electronic address: mcfox@ascension.org. 2. Department of Dermatology at the University of Rochester, Rochester, New York. 3. Department of Dermatology, University of Missouri, Columbia, Missouri. 4. Division of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts. 5. Department of Dermatology, Hospital of the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 6. Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 7. Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 8. Department of Dermatology, University of Oklahoma, Norman, Oklahoma. 9. Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin. 10. Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: While progress has been made in defining the clinical and histopathologic features of high-risk cutaneous squamous cell carcinoma (HRcSCC), optimal staging guidelines remain elusive. OBJECTIVE: We seek to guide clinical practice regarding nodal staging options for patients with HRcSCC via review of evolving definitions of HRcSCC, nodal staging options, and how nodal staging may impact treatment and affect outcomes. METHODS: This was a retrospective review of the published peer-reviewed literature regarding risk stratification, nodal staging, and treatment and outcomes for patients with HRcSCC via PubMed. RESULTS: For patients without clinical lymphadenopathy, based on literature from head and neck SCC, preoperative nodal staging with ultrasonography may be more useful than computed tomography or magnetic resonance imaging. Early nodal disease is usually curable, and therefore obtaining a sentinel lymph node biopsy specimen may be considered in those with negative imaging while we await studies of nodal staging outcomes. LIMITATIONS: More data are needed to validate the relationships between primary tumor stage and sentinel lymph node biopsy status and to determine if early detection of nodal disease impacts survival for patients with HRcSCC. CONCLUSION: It is reasonable to consider nodal staging for patients with HRcSCC (Brigham and Women's Hospital stage T2b and T3) in the absence of clinically palpable lymphadenopathy via radiographic imaging and, if negative, sentinel lymph node biopsy.
BACKGROUND: While progress has been made in defining the clinical and histopathologic features of high-risk cutaneous squamous cell carcinoma (HRcSCC), optimal staging guidelines remain elusive. OBJECTIVE: We seek to guide clinical practice regarding nodal staging options for patients with HRcSCC via review of evolving definitions of HRcSCC, nodal staging options, and how nodal staging may impact treatment and affect outcomes. METHODS: This was a retrospective review of the published peer-reviewed literature regarding risk stratification, nodal staging, and treatment and outcomes for patients with HRcSCC via PubMed. RESULTS: For patients without clinical lymphadenopathy, based on literature from head and neck SCC, preoperative nodal staging with ultrasonography may be more useful than computed tomography or magnetic resonance imaging. Early nodal disease is usually curable, and therefore obtaining a sentinel lymph node biopsy specimen may be considered in those with negative imaging while we await studies of nodal staging outcomes. LIMITATIONS: More data are needed to validate the relationships between primary tumor stage and sentinel lymph node biopsy status and to determine if early detection of nodal disease impacts survival for patients with HRcSCC. CONCLUSION: It is reasonable to consider nodal staging for patients with HRcSCC (Brigham and Women's Hospital stage T2b and T3) in the absence of clinically palpable lymphadenopathy via radiographic imaging and, if negative, sentinel lymph node biopsy.
Authors: M Rastrelli; J Soteldo; M Zonta; G Trifirò; G Mazzarol; G C Vitali; M Mosconi; A Testori Journal: Eur Surg Res Date: 2010-06-05 Impact factor: 1.745
Authors: Gary L Clayman; J Jack Lee; F Christopher Holsinger; Xian Zhou; Madeleine Duvic; Adel K El-Naggar; Victor G Prieto; Evelyn Altamirano; Susan L Tucker; Sara S Strom; Margaret L Kripke; Scott M Lippman Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Christiane A Voit; Saskia L M Gooskens; Petra Siegel; Gregor Schaefer; Alfred Schoengen; Joachim Röwert; Alexander C J van Akkooi; Alexander M M Eggermont Journal: Eur J Cancer Date: 2014-07-03 Impact factor: 9.162
Authors: Vishal A Patel; Catherine McCullum; Andrew D Sparks; Chrysalyne D Schmults; Sarah T Arron; Anokhi Jambusaria-Pahlajani Journal: Cancer Med Date: 2021-11-18 Impact factor: 4.452
Authors: Guilherme Rabinowits; Michael R Migden; Todd E Schlesinger; Robert L Ferris; Morganna Freeman; Valerie Guild; Shlomo Koyfman; Anna C Pavlick; Neil Swanson; Gregory T Wolf; Scott M Dinehart Journal: JID Innov Date: 2021-08-25